We reanalyzed the data to look for subgroups of neonates that might benefit from the 50 threshold after all. Instead of using conventional subgroup analyses we used a more robust predicted baseline risk approach. More info? Start reading here: doi.org/10.1136/bmj.k4… 2/3
We did not identify subgroups that benefit from the 50 threshold, though model needs further improvement. Suggests prophylactic platelet tx threshold of 25 appropriate for all preterm neonates, incl those at high risk of bleed/mortality. 3/3 @sanquin@LUMC_Leiden@amsterdamumc
Lots of variation in practice in this poll looking at prophylactic platelet transfusions for preterm neonates. What’s the evidence? @Atul_Monash suggested a tweetorial, which is a first for me, but here we go. 1/13
We give platelet transfusions to preterm neonates to a) treat bleeding or b) prevent bleeding (prophylaxis). Most transfusions are prophylactic. Do they reduce risk of bleeding? Up until the @PlaNeT2_trial, no one knew. doi.org/10.1182/blood-… and sciencedirect.com/science/articl…
The only previous trial by dr. Maureen Andrew and her group was published in 1993 and compared a threshold of 50x10^9 vs 150x10^9 which is higher than currently used in clinical practice. There was no difference in IVH rates between the 2 groups. doi.org/10.1016/S0022-….
Are you a neonatologist, hematologist, transfusion expert, epidemiologist or statistician and interested in neonatal transfusion research? Contact me and join a neonatal transfusion network in-the-making. Trainees and ECR welcome. @EBNEO@blooducation#epitwitter#statstwitter
I forgot to mention a very important group: fundamental researchers are also invited to join.
Wow, lots of response. Perhaps good to clarify that we will have quite a strong focus on Europe, but ofcourse are open to participants from all over the world.